Cambridge University Press eBooks
February 4, 2010
Vibeke S. Catts, Stanley V. Catts
12 citations
Facts box Phencyclidine (PCP), ketamine, D-lysergic acid diethylamide (LSD) and 3, 4-methylenedioxy-methamphetamine (MDMA) have been variously referred to as schizophrenomimetics, psychotogens, or psychotomimetics. There have been many reports that these drugs can induce psychotic symptoms (hallucinations, delusions, formal thought disorder, or catatonia-like abnormalities) in the absence of...
Journal of Psychopharmacology
February 1, 2010
G. Bedi, NT Van Dam, J. Redman
Although previous studies have examined anxiety and depression in ecstasy (±3,4-methylenedioxymethamphetamine; MDMA) users, it remains unclear whether symptoms are associated specifically with ecstasy or with polydrug use in general. We compared mean symptomatology and clinically significant symptoms in 45 ecstasy polydrug, 48 cannabis polydrug and 40 legal drug users, who completed...
Journal of Psychopharmacology
February 2010
L Craig, John E. Fisk, C Montgomery et al.
Previous findings report use of the drug ecstasy (MDMA) to be associated with lower emotional intelligence (EI), and compromised functioning in brain areas responsible for emotion. This study explored the relationship between ecstasy use, EI, mood and parenting styles. Questionnaire measures of drug use, lifestyle, parenting style and EI were obtained, with separate IQ measures for fluid...
Drug and Alcohol Dependence
February 1, 2010
Louisa Degenhardt, R. Bruno, Libby Topp
This paper examines the evidence for an MDMA or "ecstasy" dependence syndrome. Animal evidence suggests that MDMA may be a less potent reinforcer than other drugs, but that it does have dependence potential. This suggests that (a) ecstasy dependence might be less likely than dependence upon other drugs; and (b) factors related to the behavioural and psychological aspects of reward and...
Neuroscience Letters
January 29, 2010
Alejandra Arias-Cavieres, Carlos Rozas, Miguel Reyes-Parada et al.
3,4-Methylenedioxymethamphetamine (MDMA), an important recreational psychostimulant drug, was examined for its ability to alter visuo-spatial learning and synaptic plasticity. Young rats received MDMA (0.2 and 2mg/kg s.c.) twice per day for 6 days while their visuo-spatial learning was tested using the Morris Water Maze. After this, animals were sacrificed and LTP induced in hippocampal slices....
Behavioural Brain Research
January 20, 2010
Csaba Ádori, Dóra Zelena, Júlia Tímár et al.
The recreational party drug "ecstasy" (3,4-methylenedioxymethamphetamine MDMA) is particularly popular among young adults who are in the childbearing age and thus there is a substantial risk of prenatal MDMA exposure. We applied an intermittent treatment protocol with an early first injection on pregnant Wistar rats (15 mg/kg MDMA s.c. on the E4, E11 and E18 days of gestation) to examine the...
Psychopharmacology
January 18, 2010
Wendy M. Bosker, Kim P. C. Kuypers, Silke Conen et al.
45 citations
INTRODUCTION: 3,4-methylenedioxymethamphetamine (MDMA) is known to improve psychomotor function and mood when measured during daytime. However, MDMA users tend to take this drug at dance parties while staying awake for prolonged periods of time. SUBJECTS AND METHODS: This study was designed to assess dose-related residual effects of MDMA on psychomotor function and mood after a night without...
Journal of Neurochemistry
January 12, 2010
Elisa Torres, María Dolores Gutiérrez‐lópez, Érika Borcel et al.
44 citations
J. Neurochem. (2010) 10.1111/j.1471‐4159.2010.06578.x Abstract 3,4‐Methylenedioxymethamphetamine (MDMA, ‘ecstasy’) produces selective long‐lasting serotonergic neurotoxicity in rats. The drug also produces acute hyperthermia which modulates the severity of the neurotoxic response. In addition, MDMA produces signs of neuroinflammation reflected as microglial activation and an increase in the...
Annals of the New York Academy of Sciences
January 8, 2010
Bryan K. Yamamoto, Anna Moszczyńska, Gary A. Gudelsky
280 citations
The drugs of abuse, methamphetamine and MDMA, produce long‐term decreases in markers of biogenic amine neurotransmission. These decreases have been traditionally linked to nerve terminals and are evident in a variety of species, including rodents, nonhuman primates, and humans. Recent studies indicate that the damage produced by these drugs may be more widespread than originally believed....
Addiction Biology
January 2010
Rocío Martín‐Santos, Marta Torrens, Sandra Poudevida et al.
A 3-year longitudinal prospective study was conducted to compare the incidence of substance use disorders (SUD) and non-substance use disorders (NSUD) among ecstasy users and two control groups: one of cannabis users and the other of non-drug users. The 5-HTTLPR polymorphism related to NSUD was also studied. A total of 94 subjects were included: 37 ecstasy users, 23 cannabis users and 34...
Neuropsychobiology
2010
A J Matthews, R Bruno
Methylenedioxymethamphetamine affects the central serotonergic system, and there is some evidence for an association between ecstasy use (drugs sold as methylenedioxymethamphetamine) and depression. The aim of the present study was to investigate the incidence of self-reported depression and associated help-seeking among a sample of regular ecstasy users. A further aim was to examine the...
2010
Lincoln S. Hely
The so-called “party drug” 3,4-Methylenedioxymethamphetamine (MDMA, or ecstasy) may share many of the addictive properties common to other CNS stimulants. In humans MDMA is primarily consumed orally in one more pills per session. However, animal research has mostly focused on examining the effects of MDMA as a function of other routes of administration. Route of administration can have profound...
Neuropsychopharmacology
January 2010
Yoko Nawata, Takato Hiranita, Tsuneyuki Yamamoto
(+/-)-3,4-Methylenedioxymethamphetamine (MDMA, 'Ecstasy') abusers have persistent neuropsychiatric deficits including memory impairments after the cessation of abuse. On the other hand, cannabinoid CB(1) receptors have been implicated in learning/memory, and are highly expressed in the hippocampus, a region of the brain believed to have an important function in certain forms of learning and...
Clínica y Salud
2010
Lisa Wood, Barkus Emma
1 citation
Aims: The relationship between ecstasy and affective psychological symptoms are still subject to debate. We aimed to examine the relationship between Ecstasy use and self-report depression, anxiety and schizotypy. Design: Data were collected via structured remote self-report questionnaires. Participants: Participants were split into three groups: a control group with no ecstasy use, a light...
Cellular and molecular neurobiology
January 2010
Anna M S Kindlundh-Högberg, Chris Pickering, Grzegorz Wicher et al.
Ecstasy, 3,4-methylenedioxymetamphetamine (MDMA), is a recreational drug used among adolescents, including young pregnant women. MDMA passes the placental barrier and may therefore influence fetal development. The aim was to investigate the direct effect of MDMA on cortical cells using dissociated CNS cortex of rat embryos, E17. The primary culture was exposed to a single dose of MDMA and...
Addiction Biology
2010
Nora Von Ameln, Andreas Von Ameln‐mayerhofer
14 citations
ABSTRACTDespite the great popularity of 3,4‐methylenedioxymethamphetamine (MDMA, Ecstasy) as a drug of abuse, not much is known about the detailed mechanisms of the acute and subchronic effects of the drug. There is especially a lack of information about the distinct behavioural effects of its optical isomers (enantiomers) R‐ and S‐MDMA compared with the racemic RS‐MDMA. For this purpose,...
The Journal of Toxicological Sciences
2010
Asuka Kaizaki, Sachiko Tanaka, Kenji Tsujikawa et al.
14 citations
3,4-Methylenedioxymethamphetamine (MDMA) is widely abused as a psychoactive recreational drug. It is well known that MDMA induces neurotoxic damage of serotonergic nerve endings. Although drug abuse is increasing among youths, it is unclear whether recreational drugs affect the development of nerve growth. Thus, the present study examined the effect of recreational drugs, such as MDMA,...